

Extrapulmonary Features of COVID-19: A Concise Review

Sachin A Adukia¹, Radhika S Ruhatiya², Harish M Maheshwarappa³, Ramya B Manjunath⁴, Gagan N Jain⁵

ABSTRACT

Typical manifestations of coronavirus disease (COVID-19) involve the upper and lower respiratory tract. But as the pandemic surges, we are encountering numerous case reports and series of extrapulmonary presentations of COVID-19 in the outpatient department. Abundant retrospective data have also cited various extrapulmonary complications in the hospitalized COVID-19 patients. This knowledge needs to be condensed and disseminated in order to improve COVID-19 surveillance and to reduce the accidental exposure of healthcare workers. Our review suggests that gastrointestinal tract, cardiovascular system, nervous system, renal system, and manifestations due to hematological abnormalities are common masqueraders to watch out for.

Keywords: Asymptomatic, Atypical, COVID-19, Pulmonary embolism.

Indian Journal of Critical Care Medicine (2020): 10.5005/jp-journals-10071-23476

INTRODUCTION

The ongoing pandemic of coronavirus disease (COVID-19) leads to a typical presentation of respiratory features due to the affinity of the novel coronavirus (SARS-CoV-2) for the upper and lower respiratory tracts. But increasingly, the recent literature has shown varied systemic involvement. Extrapulmonary sites are being recognized as sites of disease expression and virus transmission.¹ These include the gastrointestinal tract (GIT), nervous system, cardiovascular system (CVS), renal system, eyes, and manifestations due to hematological abnormalities.

MATERIALS AND METHODS

Inclusion and Exclusion Criteria

All retrospective clinical studies, case series, and case reports with data on extrapulmonary manifestations in COVID-19 that were published from the end of December 2019 till the end of April 2020 were included. Studies that did not mention extrapulmonary manifestations were excluded.

Literature Search

The review was based on publications available on PubMed and data collected by the WHO. Search terms we used were "2019-nCoV," "SARS-CoV-2," or "COVID-19" combined with "asymptomatic," "gastrointestinal," "cardiac," "neurological," "hepatic," "hematological," "ophthalmological," "dermatological," "psychiatric," "hematological," "renal," and "atypical."

Data Extraction

We reviewed eligible studies and extracted data like country of origin, study period, demographics, systemic manifestations, and the incidence of symptoms. Two researchers, SAA and RSR, extracted the data by consensus; major disagreements were settled by the senior researcher, HM.

A case vignette at the outset will drive home the purpose of this review. A 42-year-old male was referred by his primary physician to the emergency department with a history of 8 days of testicular pain migrating into the abdomen, back, and chest. Although he had a fever 2 days back, he denied respiratory symptoms. Clinical examination revealed diffuse abdominal tenderness. Computerized

¹Department of Neurology, NH Health City, Bengaluru, Karnataka, India

^{2,3}Department of Critical Care Medicine, Mazumdar Shaw Medical Centre, Narayana Hrudayalaya, Bengaluru, Karnataka, India

⁴Department of Anesthesia, NH Health City, Bengaluru, Karnataka, India

⁵Hemraj Jain Hospital, New Delhi, India

Corresponding Author: Harish M Maheshwarappa, Department of Critical Care Medicine, Mazumdar Shaw Medical Centre, Narayana Hrudayalaya, Bengaluru, Karnataka, India, Phone: +91 8067506870, e-mail: dr.harishmm@rocketmail.com

How to cite this article: Adukia SA, Ruhatiya RS, Maheshwarappa HM, Manjunath RB, Jain GN. Extrapulmonary Features of COVID-19: A Concise Review. *Indian J Crit Care Med* 2020;24(7):575–580.

Source of support: Nil

Conflict of interest: None

tomography (CT) of the abdomen captured the lung bases. Pulmonary ground-glass opacification and consolidation consistent with pneumonia and possible colitis were noted. Two days into hospitalization, his primary physician notified his COVID-19-positive status. He had attended a biotechnology conference 2 weeks prior in a COVID-19-impacted area. Eventually, many healthcare workers (HCWs) had accidental exposure to SARS-CoV-2.²

ASYMPTOMATIC PATIENT

Individuals with positive reverse transcription-polymerase chain reaction (RT-PCR) results, who never develop any signs or clinically symptoms of COVID-19, are considered as asymptomatic. Those with positive RT-PCR results, who have no signs or symptoms of COVID-19 at testing but eventually develop symptoms, are considered as presymptomatic. About 80% COVID-19 cases in China are asymptomatic.³ The possible mechanism is that the nasal epithelial cells shelter genes for innate immunity and the viral entry-associated genes. An adequate early immune response can limit viral replication and prevent its spread into the lungs. Thus, the patient would have no or mild symptoms.⁴ The relative transmissibility of such cases is significantly smaller than

Table 1: Cardiac manifestations of COVID-19

Cardiac manifestation	Frequency reported
Coronary artery disease	4.2–25% ^{7,8}
Acute cardiac injury:	7.2% ⁷
Myocardial infarction—type 2	
Myocarditis	
Arrhythmia: Atrial arrhythmias are more common	16.7% ⁷
Cardiogenic shock	8.7% ⁷
Heart failure	49% ⁸
Cardiac tamponade	Case report ⁹
Myopericarditis	Case report ¹⁰

symptomatic ones.⁵ Evidence stating otherwise is also published.⁶ This needs further appraisal.

CARDIOVASCULAR SYSTEM

Cardiac manifestations of COVID-19 (Table 1) commonly include acute cardiac injury, shock, and arrhythmia in 7.2, 8.7, and 16.7%, respectively. Intensive care unit (ICU) patients have a higher prevalence of CVS involvement.⁷

Myocardial injury among hospitalized COVID-19 patients ranges from 7 to 28%.^{11,12} Usually, even COVID-19 patients with myocardial injury present with the typical symptoms and signs of SARS-CoV-2 infection. A minority may present with cardiac symptoms such as chest pain, palpitations,¹³ or fatigue. Evidence of myocardial injury like increased cardiac troponin or ECG abnormalities can be seen in 20%.¹¹ A direct relation between the magnitude of troponin elevation and mortality has been reported.^{7,11,12} A few others may present as an acute coronary syndrome (ACS). In such cases, the myocardial infarctions are type 2 (consequent to a mismatch between oxygen supply and demand). Putative causes for this mismatch include direct myocardial injury from hemodynamic derangement, hypoxemia, inflammatory myocarditis, stress cardiomyopathy, microvascular dysfunction or thrombosis due to hypercoagulability, or systemic inflammation with cytokine storm syndrome (CSS), which may also destabilize coronary artery plaques.¹⁴ Some patients develop systemic hyperinflammatory response with vasodilatory shock. Concomitant myocardial suppression and cardiogenic shock may ensue.¹⁵

Clinical manifestations of acute coronary artery disease (CAD) in COVID-19 are similar to those without the virus. Concurrent respiratory symptoms may or may not accompany cardiac symptoms.^{16,17} Prevalence of CAD in COVID-19 ranges from 4.2 to 25%.^{7,8} Coronary artery disease is commoner in critically ill or deceased patients.⁸

Arrhythmias in COVID-19 may remain asymptomatic or may be overshadowed by typical respiratory manifestations. However, palpitations can be presenting symptom in 7.3%.^{13,18} But more frequently, arrhythmias are an additional feature in patients presenting with conditions that may predispose to the development of arrhythmias. Examples include myocardial injury, myocardial ischemia, hypoxia, shock (septic or cardiogenic), or electrolyte disturbances like hypokalemia.¹⁹ Further, atrial arrhythmias are more common among patients requiring mechanical ventilation.²⁰

In a retrospective study, heart failure has been identified as a complication in 49% of the deceased.⁸ Heart failure may be precipitated by acute illness in preexisting known or

undiagnosed heart disease (CAD, hypertensive heart disease), or by acute myocardial injury (e.g., acute myocardial infarction, stress cardiomyopathy, CSS). A case of COVID-19-associated cardiac tamponade in a middle-aged female has been reported.⁹ Similarly, COVID-19 presenting as myopericarditis in a middle-aged female without respiratory symptoms has been reported.¹⁰ Outcomes of these cases were not mentioned.

Cardiac pathology in COVID-19 may occur through multiple mechanisms. Oudit et al. in 2009 detected viral RNA in 35% of autopsied human heart samples from severe acute respiratory distress syndrome patients. This suggested that viral infection directly causes damage to cardiomyocyte.²¹ Angiotensin converting enzyme-2 (ACE2) receptor expression in the CVS may possibly augment viral effects on the myocardial tissue.²² But, SARS-CoV-2 is not a known cardiotropic virus such that it may cause viral myocarditis. The relationship between COVID-19 and myocardial injury is yet to be characterized. Second, hypoxemia due to COVID-19 pneumonia leads to anaerobic respiration, intracellular acidosis, and influx of calcium. Subsequently, there is apoptosis of cardiomyocytes. Third, patients in ICU have higher concentrations of inflammatory factors like monocyte chemoattractant protein-1, interleukin-1 β , interferon- γ , and interferon inducible protein-10. These could accentuate the CSS.²³ The prognosis for COVID-19 patients is worse with CVS comorbidities, with mortality approaching >10%.²⁴

NEUROMUSCULAR SYSTEM

Neurological manifestations (Table 2) in COVID-19 can be categorized into three categories: central nervous system (CNS), peripheral nervous system (PNS), and skeletal muscle injury.²⁵

Overall, neurological manifestations have been recorded in 36.4% cases. Neurologic manifestations tend to occur early in the illness (median time, 1–2 days). Some patients have presented only with neurologic manifestations and no typical symptoms. Neurologic manifestations are more likely to develop in severe COVID-19 cases (45.5% vs 30%). SARS-CoV-2 probably enters the CNS through the hematogenous or retrograde neuronal route. The expression and distribution of the ACE2 receptor in the CNS and skeletal muscle tissue might explain the virus's affinity and resultant neurologic manifestations.²⁵

The presence of SARS-CoV-2 has been confirmed in the cerebrospinal fluid of COVID-19 patients by genome sequencing.²⁸ This is definitive evidence of SARS-CoV-2 causing viral encephalitis. Toxic encephalopathy can also occur in patients with COVID-19 as they tend to have severe hypoxia and viremia.³¹ The multiple drugs in the ICU also are potential culprits. SARS-CoV-2 can cause CSS leading to acute cerebrovascular disease.^{32,33} In addition, elevated levels of D-dimer and thrombocytopenia in critically ill COVID-19 patients increase the occurrence of acute cerebrovascular events.³⁴ Also, SARS-CoV-2 binds to ECA2 receptors on endothelial cells. This can lead to an increase in blood pressure, which together with thrombocytopenia and coagulation disorders can increase the risk of ischemic and hemorrhagic strokes.^{25,35}

A unique feature of the COVID-19 disease can be the absence of dyspnea, which is “an unpleasant urge to breathe.” Even the most severe cases presenting with tachypnea and tachycardia may not complain of dyspnea. In a Wuhan cohort, nearly half of those who were intubated or dead did not present dyspnea.^{26,27} Cytokine storm syndrome in COVID-19 could damage the C-pulmonary fibers and cause a total or partial loss of their function.³⁶

Table 2: Neuromuscular manifestations of COVID-19

Part of neuraxis	Manifestation	Frequency reported
Central nervous system manifestations (25%)	• Dizziness	17% ²⁵
	• Headache	13% ²⁵
	• Impaired consciousness—confusion, delirium, somnolence, stupor, coma	16% ²⁵
	• Acute cerebrovascular disease—acute ischemic stroke, intracranial hemorrhage	3% ²⁵
	• Ataxia	1% ²⁵
	• Seizure	1% ²⁵
Peripheral nervous system manifestations (9%)	• Taste impairment	5.6% ²⁵
	• Smell impairment	5% ²⁵
	• Vision impairment	1.4% ²⁵
	• Nerve pain	2.3% ²⁵
Skeletal muscle injury manifestations (11%)	• Myalgia	Up to 11% cases have muscle injury ²⁵
	• Elevated creatine kinase level >200 U/L	
Unusual manifestations	• Absence of dyspnea	46–62% ^{26,27}
	• Viral encephalitis	Case report ²⁸
	• Acute hemorrhagic necrotizing encephalopathy	Case report ²⁹
	• Guillain-Barre syndrome	Case report ³⁰

Many COVID-19 patients report sudden loss of smell or taste even in the absence of nasal symptoms.³⁷ Analysis of a European multicenter case registry has found that 85.6 and 88% of patients describe disorders of smell and taste, respectively. Of these, olfactory dysfunction is the initial symptom in 12%.³⁸

Magnetic resonance imaging (MRI) of the brain of a COVID-19 patient presenting with fever and altered sensorium showed contrast-enhancing, multifocal, symmetrical hemorrhagic lesions in both thalamus, insula, and medial temporal lobes. He was diagnosed as having acute hemorrhagic necrotizing encephalopathy,²⁹ probably due to CSS of COVID-19.³²

An elderly male was diagnosed as Guillain-Barre syndrome, and 1 week later, he had symptoms of COVID-19 with fever and dry cough. However, this relation is likely to be coincidental.³⁰

GASTROINTESTINAL SYSTEM

The overall incidence of gastrointestinal symptoms (Table 3) of COVID-19 varies from 3 to 70%.⁴⁶ SARS-CoV-2 may probably cause acute gastritis and enteritis, leading to vomiting, nausea, and diarrhea.⁴⁷ Some of the COVID-19 cases may present with digestive manifestations without any respiratory symptoms or fever. This results in unexpected exposure to the HCWs.⁴⁵

Literature reported from China has suggested that approximately 50% COVID-19 patients will have at least one gastrointestinal symptom.^{40,41} As a corollary, those with gastrointestinal symptoms are associated with a 70% increased risk of testing COVID-19 positive.⁴⁸ High expression of ACE2 in esophageal epithelial cells and the absorptive enterocytes from ileum and colon is known.⁴⁹

COVID-19 patients with GIT symptoms suffer a severe or critical illnesses such as ARDS, liver injury, and shock more frequently than in those without (22.97% vs 8.14%).⁴⁷ Fang et al. have reported that 85% of critical cases have digestive symptoms and 45% of these have diarrhea.⁵⁰ However, conflicting data have also been published. It states that among COVID-19 patients with GIT symptoms there is a nonsignificant trend toward a lower rate of ICU admission, and a significantly lower rate of death (0.0% with gastrointestinal symptoms vs 5.0% without) during short-term follow-up.

Table 3: Gastrointestinal manifestations of COVID-19

Digestive manifestation	Frequency reported
Anorexia	30–40% ^{39,40}
Diarrhea	2–50% ⁴¹
Nausea/vomiting	2–12% ^{26,39,40}
Abdominal pain	2–4% ^{39,40}
Digestive symptoms only	3–23% ^{39,40}
Abnormal liver tests:	
Aminotransferases	14–53% ^{26,42}
Bilirubin	10–18%
Virus detected in stool	50–55% ^{39,43,44}
Uncommon symptoms	Gastrointestinal bleeding ⁴⁵

These might indicate an indolent form of COVID-19 in those with gastrointestinal symptoms.⁴⁸ Gastrointestinal symptoms in COVID-19 patients are more frequent in the presence of preexisting chronic liver disease (10.81% vs 2.95% in those without).⁴⁷

RENAL MANIFESTATIONS

Studies from China has reported AKI in 25–29% critically ill patients of COVID-19 or the deceased.^{8,51} Renal abnormalities such as massive albuminuria on the 1st day of admission in 34% have been reported, while proteinuria developed in 63% of all cases during hospitalization.⁵² Another study on hospitalized COVID-19 patients has reported proteinuria and hematuria in 44% and hematuria on admission in 26.7%.⁵³ Blood urea nitrogen can be elevated in 27% COVID-19 patients, and in 66% of those who have died.⁵² Kidneys show reduced density on CT scan, suggestive of inflammation and edema. COVID-19 patients with both chronic kidney disease (CKD) and hypertension are at risk for more severe disease (3.3 vs 0.4%).^{54,55} Postulated mechanisms of kidney injury include CSS or direct cellular injury by the virus. Recently, SARS-CoV-2 has been isolated from the urine sample of an infected patient, suggesting the kidney as the target due to the expression of the ACE2 receptor on renal tubular cells.⁵⁶

OCULAR MANIFESTATIONS

Ocular involvement in COVID-19 is uncommon with prevalence between 0.9²⁶ and 31%.⁵⁷ The patient may even present with an ocular manifestation. Symptoms include watery eyes, which can be a presenting feature, followed by increased secretions, chemosis, ocular irritation, and foreign body sensation. Examination findings include unilateral or bilateral bulbar conjunctiva injection, follicular reaction of the palpebral conjunctiva, epiphora, and mild eyelid edema. These suggest follicular conjunctivitis. Unusual reports of presentation as conjunctivitis or keratoconjunctivitis⁵⁸ have been published. It generally carries a good prognosis. Positive RT-PCR results of a conjunctival swab, as well as nasopharyngeal swabs, have been obtained in two patients.⁵⁷ Possible pathogenetic mechanisms include direct inoculation of the ocular tissues from respiratory droplets or aerosolized viral particles, migration from the nasopharynx via the nasolacrimal duct, or hematogenous spread through the lacrimal gland.⁵⁹

HEMATOLOGICAL ABNORMALITIES

COVID-19 may herald a hypercoagulable state with an increased risk of venous thromboembolism (VTE) called thromboinflammation.⁶⁰ Common VTE events include pulmonary embolism (PE), deep vein thrombosis, and catheter-associated thrombosis. The rate of these events in critically ill COVID-19 patients is 33%, PE being the commonest (vs 3% in the non-ICU setting).⁶¹ Venous thromboembolism occurs despite using prophylactic-dose anticoagulation.⁶² Exact incidence of acute PE in COVID-19 is not clear, but it may be as high as 20%.⁶³ Pathogenesis of PE involves the elevated D-dimer level and thromboinflammation.^{34,60,64} Obesity also contributes to increased PE frequency.⁶⁵ Arterial events such as myocardial infarction, ischemic strokes, and peripheral arterial thromboembolism have been reported. Microvascular thrombosis may affect the lungs^{60,66} due to hypercoagulability, direct endothelial injury, complement activation, or other processes.

Thrombocytopenia in COVID-19 is well known, while the underlying mechanisms are not. It is associated with an increased risk of severe illness and mortality in COVID-19 patients.⁶⁷ However, symptomatic thrombocytopenia is uncommon. On the contrary, in COVID-19, thrombosis is common. Bleeding in the form of intracranial hemorrhage has been outlined above.

Antiphospholipid antibodies can also arise transiently in patients with critical illness⁶⁸ and rarely lead to multifocal thrombosis in critical patients. Cases of APLA syndrome in critically ill cases of COVID-19 have also been reported.⁶⁹

PSYCHIATRIC MANIFESTATIONS

Regardless of disease exposure, during an outbreak individuals with preexisting mental illnesses may experience anxiety, depression, panic attacks, somatic symptoms, posttraumatic stress disorder, delirium, psychosis, and even suicidality.⁷⁰ Healthcare workers face a lack of social support and communication, maladaptive coping, and lack of training. They can experience psychiatric morbidities due to these factors.⁷¹

DERMATOLOGICAL MANIFESTATIONS

Cutaneous manifestations have been reported in around 20% COVID-19 patients.⁷² Another review noted that cutaneous manifestations were the presenting features in 12.5%. Common manifestations in decreasing frequency are maculopapular

exanthem (morbilliform), papulovesicular rash, urticaria, painful acral red-purple papules, livedo reticularis lesions, and petechiae. Lesions are commoner on the trunk than extremities (66.7% vs 19.4%). Lesions tend to heal spontaneously in 10 days.⁷³ A hypothesis states that cutaneous blood vessels contain viral particles. Blood immune complexes can activate cytokines and cause lymphocytic vasculitis. This can result in vasodilatation and spongiosis.⁷⁴

UNUSUAL PRESENTATIONS

All the cases below had an atypical presentation; they were diagnosed as COVID-19 by RT-PCR. The CT chest was done wherever necessary. A middle-aged female with arthralgia with fever and thrombocytopenia subsequently developed pneumonia and diagnosed as COVID-19.⁷⁵ An elderly female presented with syncope and orthostatic hypotension, and 2 days later with altered sensorium. Eventually, COVID-19 was confirmed.⁷⁶ A COVID-19 patient presented after 12 days of discharge with hemoptysis, dyspnea, and worsening chest pain due to segmental PE with no risk factor for VTE.⁷⁷ A middle-aged female presented with dark-colored urine, followed by mild fever, and liver function derangement favoring acute hepatitis. This was an acute, nonicteric hepatitis presentation of COVID-19.⁷⁸ A hospitalized case of COVID-19 with respiratory distress developed acute liver failure alongside multiorgan failure.⁷⁹

LIMITATIONS OF STUDY

Knowledge about the COVID-19 pandemic is evolving. We included data only up to April 30, 2020. By the time this write-up is published, newer data might become available. Second, we reviewed case reports, case series, retrospective studies, and registries. All of these tend to be inherently biased.

CONCLUSION

Up-to-date knowledge of atypical and extrapulmonary manifestations can help to increase surveillance of COVID-19 and can protect the HCWs. A high index of suspicion for COVID-19 is required when tackling patients with extrapulmonary manifestations. Notable manifestations among them are gastrointestinal—*anorexia, diarrhea*; cardiovascular—*arrhythmias, myocarditis*; consequences of hypercoagulability—*pulmonary embolism, ACS, ischemia stroke*.

REFERENCES

1. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004;203(2):631–637. DOI: 10.1002/path.1570. PMID: 15141377; PMCID: PMC17167720.
2. Kim J, Thomsen T, Sell N, Goldsmith AJ. Abdominal and testicular pain: an atypical presentation of COVID-19. *Am J Emerg Med* 2020;38(7):1542.e1–1542.e3. DOI: 10.1016/j.ajem.2020.03.052.
3. World Health Organization, Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). 2020. <https://www.who.int/docs/default-source/coronaviruse/who-chinajoint-mission-on-covid-19-final-report.pdf>.
4. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med* 2020(5):1–7. DOI: 10.1038/s41591-020-0868-6.

5. He D, Zhao S, Lin Q, Zhuang Z, Cao P, Wang MH, et al. The relative transmissibility of asymptomatic cases among close contacts. *Int J Infect Dis* 2020. DOI: 10.1016/j.ijid.2020.04.034.
6. Yin G, Jin H. Comparison of transmissibility of coronavirus between symptomatic and asymptomatic patients: Reanalysis of the Ningbo COVID-19 data. *JMIR Public Health Surveill* 2020;6(2):e19464. DOI: 10.2196/19464.
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323(11):1061–1069. DOI: 10.1001/jama.2020.1585.
8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020. 368. DOI: 10.1136/bmj.m1091.
9. Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. *Eur Heart J* 2020;41(22):2130. DOI: 10.1093/eurheartj/ehaa253.
10. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA cardiology* 2020. DOI: 10.1001/jamacardio.2020.1096.
11. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA cardiology* 2020. DOI: 10.1001/jamacardio.2020.0950.
12. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. *Prog Cardiovasc Dis* 2020. DOI: 10.1016/j.pcad.2020.03.001.
13. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020;133(9):1025–1031. DOI: 10.1097/CM9.0000000000000744.
14. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherosclerosis: JACC review topic of the week. *J Am Coll Cardiol* 2018;72(17):2071–2081. DOI: 10.1016/j.jacc.2018.08.1043.
15. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. *J Heart Lung Transplant* 2020;39(5):405–407. DOI: 10.1016/j.healun.2020.03.012.
16. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nature Reviews Cardiology* 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
17. Dong N, Cai J, Zhou Y, Liu J, Li F. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. *JACC: Heart Failure* 2020;8(6):515–517. DOI: 10.1016/j.jchf.2020.04.001.
18. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. *J Am Coll Cardiol* 2020;75(18):2352–2371. DOI: 10.1016/j.jacc.2020.03.031.
19. Lazzarini PE, Boutjdir M, Capocchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap!. *Circulation* 2020(1). DOI: 10.1161/CIRCULATIONAHA.120.047293.
20. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of COVID-19 in New York city. *N Engl J Med* 2020;382(24):2372–2374. DOI: 10.1056/NEJM2010419.
21. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur J Clin Invest* 2009;39(7):618–625. DOI: 10.1111/j.1365-2362.2009.02153.x.
22. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *The Lancet* 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8.
23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.
24. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
25. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA neurology* 2020;77(6):1–9. DOI: 10.1001/jama.2020.1127.
26. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.
27. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020;92(6):552–555. DOI: 10.1002/jmv.25728.
28. Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH. First case of 2019 novel coronavirus disease with encephalitis. *ChinaXiv* 2020;202003:00015.
29. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology* 2020. 201187. DOI: 10.1148/radiol.2020201187.
30. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *The Lancet Neurology* 2020;19(5):383–384. DOI: 10.1016/S1474-4422(20)30109-5.
31. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Mil Med Res* 2020;7(1):11. DOI: 10.1186/s40779-020-00240-0.
32. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. *The Lancet* 2020;395(10229):1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.
33. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies. *Zhonghua Shao Shang Za Zhi. Chin J Bur* 2020;36(6):E005. doi: 10.3760/cma.j.cn501120-20200224-00088.
34. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol* 2020;92(6):568–576. DOI: 10.1002/jmv.25748.
35. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al. Acute cerebrovascular disease following COVID-19: a single, retrospective, observational study. *Lancet* 2020. DOI: 10.2139/ssrn.3550025.
36. Omar S, Clarke R, Abdullah H, Brady C, Corry J, Winter H, et al. Respiratory virus infection up-regulates TRPV1, TRPA1 and ASIC3 receptors on airway cells. *PLoS ONE* 2017;12(2):e0171681. DOI: 10.1371/journal.pone.0171681.
37. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. *Clin Infect Dis* 2020. DOI: 10.1093/cid/ciaa330.
38. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory Dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter european study. *Eur Arch Otorhinolaryngol* 2020(8):1–1. DOI: 10.1007/s00405-020-05965-1.
39. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease Severity: Clinical presentation, stool viral RNA testing, and outcomes. *Am J Gastroenterol* 2020;115(6):916–923. DOI: 10.14309/ajg.0000000000000664.
40. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol* 2020(5):115. DOI: 10.14309/ajg.0000000000000620.
41. D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. *Clin Gastroenterol Hepatol* 2020;18(8):1663–1672. DOI: <https://doi.org/10.1016/j.cgh.2020.04.001>.

42. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: Management and challenges. *Lancet Gastroenterol Hepatol* 2020;5(5):428–430. DOI: 10.1016/S2468-1253(20)30057-1.
43. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterol* 2020;158(6):1831–1833. DOI: 10.1053/j.gastro.2020.02.055.
44. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020;5(5):434–435. DOI: 10.1016/S2468-1253(20)30083-2.
45. Aroniadis OC, DiMaio CJ, Dixon RE, Elmunzer BJ, Kolb JM, Mendelsohn R, et al. Current knowledge and research priorities in the digestive manifestations of COVID-19. *Clin Gastroenterol Hepatol* 2020;18(8):1682–1684. DOI: 10.1016/j.cgh.2020.04.039.
46. Tian Y, Rong L, Nian W, He Y. Gastrointestinal features in COVID-19 and the possibility of faecal transmission. *Aliment Pharmacol Ther* 2020;51(9):843–851. DOI: 10.1111/apt.15731.
47. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* 2020;69(6):1002–1009. DOI: 10.1136/gutjnl-2020-320926.
48. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. *Gastroenterol* 2020. S0016-5085(20)30490-X 10.1053/j.gastro.2020.04.017.
49. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nat* 2020 ;579(7798):265–269. DOI: 10.1038/s41586-020-2008-3.
50. Fang D, Ma J, Guan J, Wang M, Song Y, Tian D. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. *Chin J Dig* 2020;40(2020-02-23).
51. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8(5):475–481. DOI: 10.1016/S2213-2600(20)30079-5.
52. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, Caution on Kidney Dysfunctions of 2019-nCoV Patients medRxiv; 2020.10.1101/2020.02.18.
53. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. *MedRxiv* 2020;97(5):829–838. DOI: 10.1016/j.kint.2020.03.005.
54. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in china: a nationwide analysis. *Europ Respirat J* 2020;55(5):2000547. DOI: 10.1183/13993003.00547-2020.
55. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol* 2020(6):1–2. DOI: 10.1007/s11255-020-02451-9.
56. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nat* 2003;426(6965):450–454. DOI: 10.1038/nature0214.
57. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmol* 2020;138(5):575–578. DOI: 10.1001/jamaophthalmol.2020.1291.
58. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19): a case report. *Can J Ophthalmol* 2020. DOI: 10.1016/j.cjco.2020.03.003.
59. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. *Ocul Immunol Inflamm* 2020;28(3):391–395. DOI: 10.1080/09273948.2020.1738501.
60. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost* 2020;18(7):1559–1561. DOI: 10.1111/jth.14849.
61. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. Preprints 2020. 2020040345. DOI: 10.20944/preprints202004.0345.v1.
62. Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thromb Res* 2020;191:148–150. DOI: 10.1016/j.thromres.2020.04.041.
63. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. *Circulation* 2020. DOI: 10.1161/CIRCULATIONAHA.120.047430.
64. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography. *Thromb Res* 2020. DOI: 10.1016/j.thromres.2020.04.011.
65. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. Lille intensive care COVID-19 and Obesity study group. High prevalence of Obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity* 2020;28(7):1195–1199. DOI: 10.1002/oby.22831.
66. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Translat Res* 2020;220:1–13. DOI: 10.1016/j.trsl.2020.04.007.
67. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clinica Chimica Acta* 2020;506:145–148. DOI: 10.1016/j.cca.2020.03.022.
68. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. *Semin Arthritis Rheum* 2002;31(4):256–263. DOI: 10.1053/sarh.2002.28303.
69. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med* 2020;382(17):e38. DOI: 10.1056/NEJMc2007575.
70. Hall RCW, Hall RCW, Chapman MJ. The 1995 Kikwit Ebola outbreak: lessons hospitals and physicians can apply to future viral epidemics. *Gen Hosp Psychiatry* 2008;30(5):446–452. DOI: 10.1016/j.genhosppsych.2008.05.003.
71. Naushad VA, Bierens JJ, Nishan KP, Firjeeth CP, Mohammad OH, Maliyakkal AM, et al. A systematic review of the impact of disaster on the mental health of medical responders. *Prehosp Disaster Med* 2019;34(6):632–643. DOI: 10.1017/S1049023X19004874.
72. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020(5). DOI: 10.1111/jdv.16387.
73. Sachdeva M, Gianotti R, Shah M, Lucia B, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. *J Dermatol Sci* 2020;98(2):75–81. DOI: 10.1016/j.jdermsci.2020.04.011.
74. Gianotti R. COVID 19 and the skin—heuristic review. *Derma Sprint* 2020. In press.
75. Joob B, Wiwanitkit V. Arthralgia as an initial presentation of COVID-19: observation. *Rheumatol Int* 2020(5):1. DOI: 10.1007/s00296-020-04561-0.
76. Singhania N, Bansal S, Singhania G. An atypical presentation of novel coronavirus disease 2019 (COVID-19). *Am J Med* 2020;133(7):e365–e366. DOI: 10.1016/j.amjmed.2020.03.026.
77. Casey K, Itean A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. *Am J Emerg Med* 2020;38(7):1544.e1–1544.e3. DOI: 10.1016/j.ajem.2020.04.011.
78. Wander P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis. *Am J Gastroenterol* 2020;115(6):941–942. DOI: 10.14309/ajg.0000000000000660.
79. Weber S, Mayerle J, Irlbeck M, Gerbes AL. Severe liver failure during SARS-CoV-2 infection. *Gut* 2020;69(7):1365–1367. DOI: 10.1136/gutjnl-2020-321350.